Literature DB >> 26700205

ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action.

Guowei Gu1, Suzanne A W Fuqua2.   

Abstract

Wang and colleagues demonstrate that digital droplet PCR (ddPCR) identified ESR1 mutations in 7% of primary breast cancers. ESR1 mutations were also readily detected in metastatic tissues and circulating tumor DNA in the blood. These results suggest that ddPCR may be amendable for monitoring tumor burden, and to predict relapse. See related article by Wang et al., p. 1130. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26700205      PMCID： PMC4775407          DOI： 10.1158/1078-0432.CCR-15-2549

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  11 in total

1.  Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.

Authors:  Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

2.  Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy-Resistant Breast Cancer.

Authors:  Suzanne E Wardell; Matthew J Ellis; Holly M Alley; Koleen Eisele; Todd VanArsdale; Stephen G Dann; Kim T Arndt; Tina Primeau; Elizabeth Griffin; Jieya Shao; Robert Crowder; Jin-Ping Lai; John D Norris; Donald P McDonnell; Shunqiang Li
Journal:  Clin Cancer Res       Date:  2015-05-19       Impact factor: 12.531

3.  Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens.

Authors:  Takashi Takeshita; Yutaka Yamamoto; Mutsuko Yamamoto-Ibusuki; Toko Inao; Aiko Sueta; Saori Fujiwara; Yoko Omoto; Hirotaka Iwase
Journal:  Transl Res       Date:  2015-09-14       Impact factor: 7.012

Review 4.  The role of estrogen receptors in breast cancer metastasis.

Authors:  S A Fuqua
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Authors:  L De Mattos-Arruda; B Weigelt; J Cortes; H H Won; C K Y Ng; P Nuciforo; F-C Bidard; C Aura; C Saura; V Peg; S Piscuoglio; M Oliveira; Y Smolders; P Patel; L Norton; J Tabernero; M F Berger; J Seoane; J S Reis-Filho
Journal:  Ann Oncol       Date:  2014-07-09       Impact factor: 32.976

6.  Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients.

Authors:  Peilu Wang; Amir Bahreini; Rekha Gyanchandani; Peter C Lucas; Ryan J Hartmaier; Rebecca J Watters; Amruth R Jonnalagadda; Humberto E Trejo Bittar; Aaron Berg; Ronald L Hamilton; Brenda F Kurland; Kurt R Weiss; Aju Mathew; Jose Pablo Leone; Nancy E Davidson; Marina N Nikiforova; Adam M Brufsky; Tadeu F Ambros; Andrew M Stern; Shannon L Puhalla; Adrian V Lee; Steffi Oesterreich
Journal:  Clin Cancer Res       Date:  2015-10-23       Impact factor: 12.531

7.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

8.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

9.  Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.

Authors:  Min Yu; Aditya Bardia; Nicola Aceto; Francesca Bersani; Marissa W Madden; Maria C Donaldson; Rushil Desai; Huili Zhu; Valentine Comaills; Zongli Zheng; Ben S Wittner; Petar Stojanov; Elena Brachtel; Dennis Sgroi; Ravi Kapur; Toshihiro Shioda; David T Ting; Sridhar Ramaswamy; Gad Getz; A John Iafrate; Cyril Benes; Mehmet Toner; Shyamala Maheswaran; Daniel A Haber
Journal:  Science       Date:  2014-07-11       Impact factor: 47.728

10.  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.

Authors:  Weiyi Toy; Yang Shen; Helen Won; Bradley Green; Rita A Sakr; Marie Will; Zhiqiang Li; Kinisha Gala; Sean Fanning; Tari A King; Clifford Hudis; David Chen; Tetiana Taran; Gabriel Hortobagyi; Geoffrey Greene; Michael Berger; José Baselga; Sarat Chandarlapaty
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330
View more
  7 in total

1.  ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg".

Authors:  Suzanne A W Fuqua; Yassine Rechoum; Guowei Gu
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

2.  Estrogen-independent Myc overexpression confers endocrine therapy resistance on breast cancer cells expressing ERαY537S and ERαD538G mutations.

Authors:  Liqun Yu; Lawrence Wang; Chengjian Mao; Darjan Duraki; Ji Eun Kim; Rui Huang; William G Helferich; Erik R Nelson; Ben Ho Park; David J Shapiro
Journal:  Cancer Lett       Date:  2018-11-09       Impact factor: 8.679

Review 3.  The Impact of ESR1 Mutations on the Treatment of Metastatic Breast Cancer.

Authors:  Sasha M Pejerrey; Derek Dustin; Jin-Ah Kim; Guowei Gu; Yassine Rechoum; Suzanne A W Fuqua
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

4.  Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors.

Authors:  Yuechao Zhao; Mary J Laws; Valeria Sanabria Guillen; Yvonne Ziegler; Jian Min; Abhishek Sharma; Sung Hoon Kim; David Chu; Ben Ho Park; Steffi Oesterreich; Chengjian Mao; David J Shapiro; Kendall W Nettles; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  Cancer Res       Date:  2017-09-13       Impact factor: 12.701

5.  Detection of Activating Estrogen Receptor Gene (ESR1) Mutations in Single Circulating Tumor Cells.

Authors:  Carmela Paolillo; Zhaomei Mu; Giovanna Rossi; Matthew J Schiewer; Thomas Nguyen; Laura Austin; Ettore Capoluongo; Karen Knudsen; Massimo Cristofanilli; Paolo Fortina
Journal:  Clin Cancer Res       Date:  2017-07-05       Impact factor: 12.531

Review 6.  Estrogen receptors in breast and bone: from virtue of remodeling to vileness of metastasis.

Authors:  I Bado; Z Gugala; S A W Fuqua; X H-F Zhang
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

Review 7.  Estrogen receptor-α signaling in post-natal mammary development and breast cancers.

Authors:  Marine Adlanmérini; Elodie Chantalat; Mariam Rusidzé; I Raymond-Letron; Surya Cayre; Jean-François Arnal; Marie-Ange Deugnier; Françoise Lenfant
Journal:  Cell Mol Life Sci       Date:  2021-06-22       Impact factor: 9.261
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.